Assistant Professor, Internal Medicine, University of Michigan Medical School
Hematology
Dr. Dale L. Bixby, MD
|
|
Give Review
Dale Bixby is an expert in the field of Hematology. He went to medical school at University of Michigan Medical School. He received awards:"Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Dale Bixby is a published doctor as well. He has 26 publications published. The latest was: CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal... Dale Bixby is registered with Medicare and accepts Medicare payments.
Publications
- Shared clonal cytogenetic abnormalities in aberrant mast Cells and leukemic myeloid blasts detected by single nucleotide polymorphism microarray-based whole-genome sca...
- FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.
- Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with Acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
- Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for Acute myeloid leukemia in rem...
- Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo.
- Mutations in linker histone genes HIST1H1 B, C, D and E, OCT2 (POU2F2), IRF8 and ARID1A underlying the pathogenesis of follicular Lymphoma.
- BCR-ABL inhibitors: Updates in the management of patients with chronic-phase chronic myeloid Leukemia.
- CD133+ hematopoietic progenitor Cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression.
- Ponatinib in patients with refractory Acute myeloid leukaemia: findings from a phase 1 study.
- Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory Hematological malignancies.
- Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous Leukemia.
- Ponatinib in refractory Philadelphia chromosome-positive Leukemias.
- Managing inadequate responses to frontline treatment of chronic myeloid Leukemia: A case-based review.
- Somatic mutations in the transcriptional corepressor gene BCORL1 in adult Acute myelogenous leukemia.
- Genetic structure and diversity among sheep breeds in the United States: identification of the major gene pools.
- p53 stabilization induces apoptosis in chronic myeloid Leukemia blast crisis cells.
- HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor Cells.
- Seeking the causes and solutions to imatinib-resistance in chronic myeloid Leukemia.
- Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult Acute myelogenous leukemia.
- HIV-1 infects multipotent progenitor Cells causing Cell death and establishing latent Cellular reservoirs.
- Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid Leukemia and recent therapeutic strategies to overcome resistance.
- The pre-clinical development of MDM2 inhibitors in chronic lymphocytic Leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apopto...
- Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.
- Characterization of human non-small Cell lung cancer (NSCLC) Cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens.
- CD80 expression in an HLA-A2-positive human non-small Cell lung cancer Cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T Cells derived from a normal...
Schools
University of Mi Med Sch
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Michigan Hospitals and Health Centers -
University of Michigan Medical School
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1952423816 | |
| NPPES Provider LastName | BIXBY | |
| NPPES Provider FirstName | DALE | |
| NPPES Provider ZIPCode | 481095911 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology | |
| Total Claim Count | 453.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952423816 |
| Last Name Of The Provider | BIXBY |
| First Name Of The Provider | DALE |
| View All |
Similar Doctors
|
|
Dr. Mark S. Kaminski, MD |
|
|
Dr. Harry P. Erba, MD |
|
|
Dr. Asra Z. Ahmed, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Max S. Wicha, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paula L. Bockenstedt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey B. Smerage, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Megan S. Lim, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Vaibhav Sahai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David C. Smith, MD |
|
|
Dr. Christine M. Veenstra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Assuntina G. Sacco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grace Y. Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel Lebovic, MD |
|
|
Dr. Vicki L. Goodman, MD |
|
|
Dr. Jie Wang, MD |
|
|
Dr. Mary L. Varterasian, MD |
|
|
Dr. Maria A. Pletneva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zachery R. Reichert, MD |